Consistent with previous studies [49–51], the present study identified increases in the expression of the general inflammation marker MMP12 and the Th17 marker CCL20 in AD skin lesions, whereas ADSC treatment reversed these changes. The gene discussed is CCL20; the disease is Alzheimer disease.